Qiao, Xiaohang
van der Zanden, Sabina Y.
Li, Xiaoyang
Tan, Minkang
Zhang, Yunxiang
Song, Ji-Ying
van Gelder, Merle A.
Hamoen, Feija L.
Janssen, Lennert
Zuur, Charlotte L.
Pang, Baoxu
van Tellingen, Olaf
Li, Junmin
Neefjes, Jacques
Funding for this research was provided by:
Riki foundation
European Research Council (ERCOPE 694307)
KWF Kankerbestrijding (KWF 11356)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO 024.002.009)
Article History
Received: 22 November 2023
Accepted: 28 May 2024
First Online: 4 June 2024
Declarations
:
: All mouse experiments were approved by the Animal Ethics Committee of the NKI and were performed according to institutional and national guidelines. The retrospective clinical study was approved by the ethics committee of Ruijin Hospital, and all patients provided written informed consent.
: J.N. is a shareholder in NIHM that aims to produce Acla for clinical use. The authors do not declare any other competing interests.